Exploring the Role of a Novel HPV16-Targeted Cancer T-cell Stimulating Immunotherapy (TSI) (Versamune HPV) for Human Papilloma Virus (HPV) Positive Head and Neck Cancer (HNSCC) - Episode 8

Future Considerations for the Treatment of R/M HPV-Positive HNSCC

,

Panelists discuss how emerging areas in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) research include novel immunotherapy combinations, biomarker development for treatment selection, targeted therapies against new molecular pathways, and strategies to overcome resistance to existing treatments.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Introduction and Incidence of HPV-Positive Head and Neck Cancer
    EP. 2: Understanding HPV-Positive HNSCC: Disease Presentation and Risk Factors
    EP. 3: Navigating Treatment for HPV-Positive HNSCC Patients
    EP. 4: Academic Perspectives for the Management of HPV-Positive HNSCC
    EP. 5: Updates From VERSATILE-002: Pembrolizumab Plus PDS0101 (HPV-16–Targeted Cancer Vaccine) in HPV-Positive HNSCC
    EP. 6: Emerging Phase 3 Trial: Pembrolizumab Plus PDS0101 (HPV-16 Targeted Cancer Vaccine) in HPV-Positive HNSCC (VERSATILE-003)
    EP. 7: Treatment Insights for R/M HPV-Positive HNSCC
    Now Viewing
    EP. 8: Future Considerations for the Treatment of R/M HPV-Positive HNSCC

    Video content above is prompted by the following:

    • What areas for future research in the treatment of R/M HNSCC should clinicians keep an eye on?

    x